A first-ever World Health Organization assessment of the growing problem calls for rapid changes to avoid the misery and deaths of a potential “post-antibiotic era”
Dangerous antibiotic-resistant bacteria and other pathogens have now emerged in every part of the world and threaten to roll back a century of medical advances. That’s the message from the World Health Organization in its first global report on this growing problem, which draws on drug-resistance data in 114 countries.
From iodine eyedrops that prevent blindness in children to cholesterol testing to early discoveries that led to in vitro fertilization, the Los Angeles Biomedical Research Institute has made innovative scientific breakthroughs with worldwide implications since 1962.
But the renowned research institute hasn’t profited much from the groundbreaking technologies it birthed.
A new study which shows a specific form of garlic that you can buy in any health food store; may control, maybe even reverse heart disease.
Although previous studies have focused on garlic’s effect on cholesterol, this research done by Dr. Matthew Budoff, of LABiomed at Harbor General Hospital in Carson, is the first to look at its direct effect on the hearts arteries.
Budoff told NBC4’s Dr. Bruce Hensel that the reserchers wanted “to see if there is actually benefit to the arteries themselves; if there’s heart disease benefit by taking aged garlic extract.”
MedicalResearch.com Interview with:
Rine Nakanishi, MD, PhD
Los Angeles Biomedical Research Institute
MedicalResearch.com: What are the main findings of the study?
Dr. Nakanishi: With growing evidence that a measurement of the buildup of calcium in
coronary arteries can predict heart disease risk, Los Angeles Biomedical
Research Institute (LA BioMed) researchers found that the process of
“calcium scoring” was also accurate in predicting the chances of dying among
adults with little or no traditional risk factor of heart disease.
With growing evidence that a measurement of the buildup of calcium in coronary arteries can predict heart disease risk, Los Angeles Biomedical Research Institute (LA BioMed) researchers found that the process of “calcium scoring” was also accurate in predicting the chances of dying of heart disease among adults with little or no known risk of heart disease.
As one of the most common and deadliest “Superbugs,” Acinetobacter baumannii, continues to grow in strength and prevalence, Los Angeles Biomedical Research Institute (LA BioMed) infectious disease specialist Brad Spellberg, MD, is launching a study to determine if a vaccine could halt the spread of these hospital-acquired infections.
Continuing a tradition of recognizing its most outstanding physician-researchers, the Los Angeles Biomedical Research Institute (LA BioMed) will celebrate the many accomplishments of Drs. Joel D. Kopple and Robert S. Hockberger on May 1 at Legends 2014 at the Torrance Marriott South Bay.
Investigator(s):
The Lundquist Institute
Studies Suggest Coronary Calcium Scores Can Assess Long-Term Risk for Heart Disease
Despite being available for decades, CT-based coronary artery calcium scoring has been subject to debate among doctors on whether, and how, it should be used to inform patient care. Utilizing data from five separate studies, researchers have concluded that coronary artery calcium scoring can provide an early indication of a person’s long-term risk for heart disease. The results of the five studies were presented as part of ACC.14.
Seeking new therapies for the treatment of social anxiety in autistic adults, researchers at the Los Angeles Biomedical Research Institute (LA BioMed) announced today that they are initiating a novel study into the safety and effectiveness of MDMA-assisted therapy.
Emmaus Life Sciences, Inc. (the “Company,” or “Emmaus”), a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases, today announced that preliminary top-line results of its Phase 3 clinical trial evaluating the safety and efficacy of its treatment for sickle cell anemia and sickle beta-0 thalassemia met both the primary and secondary endpoints of the clinical trial.